Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.45 |
| ▸ | DHODH | Q02127 | 12/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
| ▸ | STK3 | Q13188 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23693808 | 0.89 | MAP2K1 (0.46) | MAP2K1MAP2K2DHODH | |
| SCHEMBL29781357 | 0.84 | MAP2K1 (0.64) | MAP2K1MAP2K2DHODH | |
| SCHEMBL4860207 | 0.80 | MAP2K1 (0.70) | MAP2K1MAP2K2IDO1AURKAPRKCB | |
| SCHEMBL23694236 | 0.80 | MAP2K1 (0.33) | MAP2K1MAP2K2DHODH | |
| SCHEMBL1341919 | 0.78 | KDM4E (0.52) | MAP2K1MAP2K2 | |
| SCHEMBL24927442 | 0.76 | MAP2K1 (0.65) | MAP2K1MAP2K2 | |
| SCHEMBL29425449 | 0.76 | MAP2K1 (0.65) | MAP2K1MAP2K2 | |
| Hydrochloric Acid SCHEMBL30823014 | 0.74 | AURKA (0.40) | MAP2K1MAP2K2DHODHIDO1AURKA | |
| SCHEMBL31502280 | 0.74 | MAP2K1 (0.64) | MAP2K1MAP2K2IDO1AURKAPRKCB | |
| SCHEMBL10148375 | 0.71 | ACMSD (0.53) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803024-B | Compositions comprising aryl amide derivatives | 中外制药株式会社 | 2025-01-10 | — | — | CN | disclosed |
| CN-114929669-B | Aryl amide derivatives with antitumor activity | 中外制药株式会社 | 2024-11-29 | — | — | CN | disclosed |
| CN-117677607-A | Process for producing aryl amide derivative | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4186506-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-31 | — | — | EP | disclosed |
| CN-115803024-A | Composition comprising arylamide derivatives | 中外制药株式会社 | 2023-03-14 | — | — | CN | disclosed |
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
| CN-114929669-A | Arylamide derivatives having antitumor activity | 中外制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022018875-A1 | ARYLAMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CELL PROLIFERATION DISEASES | 中外製薬株式会社 | 2022-01-27 | — | — | WO | disclosed |
| WO-2021149776-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | 中外製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | MAP2K1 17/4885MAP2K2 11/4885DHODH 2249/4885 |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | MAP2K1 162/4885MAP2K2 132/4885DHODH 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.